The Ludwig Institute for Cancer Research Ltd (LICR) is a global non-profit organisation committed to improving the understanding and control of cancer though integrated laboratory and clinical discovery.
Founded in 1971 by the American businessman Daniel K. Ludwig, the core of the LICR is concentrated at ten research locations: two each in Australia, Sweden and the USA; and one each in Belgium, Brazil, Switzerland and the UK. The LICR engages leading scientists and clinicians in an integrated laboratory and clinical research effort to understand and confront the global challenge of cancer.
The Oxford Branch of the LICR was established in 2007, following the relocation of the LICR's UK presence from London. The overarching focus of the Oxford Branch is to identify key molecular switches that drive cancer progression and cellular heterogeneity, with the aim of benefitting patients.
Within cancers multiple sub-populations of cells can co-exist, each with differing biological properties. Some may exhibit features of differentiation and others proliferate, while other cells possess stem cell-like properties enabling them to initiate new tumours and provide a pool of therapeutically resistant cells. As a result, tumour cell heterogeneity is a major challenge: we need to understand its origins and the molecular switches that control it to develop more effective cancer therapies.
Led by the Branch's Director Professor Xin Lu, we aim to address this challenge through our research and the translation of our discoveries into the clinic.
Podcast created by NDM for the Ludwig Institute for Cancer Research.
Welcome to the Oxford Branch of the Ludwig Institute for Cancer Research at the University of Oxford.
We are based in the Old Road Campus Research Building, as part of the Nuffield Department for Clinical Medicine.
The Ludwig Institute for Cancer Research is a global non-profit research organisation, committed to improving the control of cancer through integrated laboratory and clinical research. We receive core funding from the Ludwig Institute, as well as funding in the form of grants from other agencies worldwide.
One of the major challenges in developing effective anti-cancer therapies is tumour cell heterogeneity. Within cancers, multiple subpopulations can co-exist, each with different biological properties. Some may exhibit features of differentiation, while others possess stem cell-like properties enabling them to initiate new tumours and provide a pool of therapeutically resistant cells. To develop more effective anti-cancer therapies we need to understand the origins of molecular switches that determine cancer cell heterogeneity. Our Institute specialises in research focussed on identifying these switches, with the aim of sensitising cancer cells to therapy and improving patients' response to treatment.
We have seven, integrated research groups at the Institute with overlapping research interests. One of the main research focuses of the Institute is the identification of molecular switches involved in cell growth or death by Professor Xin Lu's group, stem cells and differentiation by Professor Colin Goding's group and tumour vascularisation by Dr Sarah De Val's group. This is complemented by the work of Professor Skirmantas Kriaucionis group's work on the epigenetic regulation of gene expression at the genome-wide level, Dr John Christianson's group's research on the post-translational regulation of molecular switches, Professor Gareth Bond's group's identification of molecular genetic signatures of cancer predisposition, progression and response, and Dr Richard Bryant's group's research on prostate cancer progression.
Detailed information regarding each group's research interests can be found on our website.
We conduct cutting edge molecular and cellular biology research, using state-of-the-art equipment. Our Imaging Facility enables researchers to observe a wide variety of fixed or live samples over a wide range of magnifications, from entire organisms to sub cellular localisations, and includes the latest Multiphoton Confocal microscope from Zeiss.
We are at the heart of cancer research in Oxford, and cooperate widely with researchers and clinicians across the World.
The Institute is truly international, with over 80% of our staff having come to us from outside the UK.
Research studentships are available each year, and our students benefit from studying at a leading international research institute that is part of one of most highly regarded Universities in the world.
If you are interested in collaborating with us, or joining us, please see our website or contact us for further information.